The IMS, leading provider of information, services and
technology for the healthcare industry, covering markets in 100+
countries around the world has announced its latest report with
regard to and in consideration of worldwide pharmaceutical industry
as of July 2012. As it has been reported, the pharmerging companies
will grow by USD 150-165Bn over five years. Generic and other
products will account for approximately 83% of the increase. In
pharmerging markets the rising incomes, combined with continued low
costs for medicines will drive significant increases in
affordability of basic medicines.The patients face substantial
out-of-pocket costs in these markets, with a few exceptions, which
limits the usage of brands and expensive newer medicines.
Government-supported or funded programs will continue to increase
access to medicines, limit patients' exposure to costs and
encourage greater use of medicines. In the report, Turkey has been
defined as one of the pharmerging countries (tier 3 ) with a change
in ranking over prior five years in parallel with its economic
development. Turkey's pharmaceutical industry has growth about
30% that is considerable when compared with the worldwide market
with the growth rate of 4,6%. Since 2006, 13 local companies have
restructured its corporate mechanism to go ahead through a foreign
partnership. The M&A operations in Turkish pharmaceutical
industry, notwithstanding the regulations that limit the sales of
companies, are still ongoing. It is expected USD five million
foreign capital to penetrate into Turkish market within coming ten
years. It is also obviously observed that the interest of foreign
capital rise the importance of employment. The estimated rates
figure out that there are 25.000 persons employed in Turkish
pharmaceutical industry by 300 companies that 57 of them are
multinational. The pharmaceutical industry shall be considered as a
whole if the Turkish market is question. However in consideration
of the effective and qualified labor force in Turkish market, there
is no obstacle for multination manufacturers to set their R&D
units in Turkey alike they did the same in similar countries in the
past. The result we have launched when we evaluated the M&A
operations of past five years, the major local manufacturers are
largely acquired by foreign manufacturers that is a rule of
distribution mechanism as we have experienced up to date. In
evaluation of IMS report and the potential of Turkey in
pharmaceutical industry we are in the opinion of that, only the
minor manufacturers or the manufacturers still hesitant to proceed
in Turkish market will be potential purchasers of local distributor
against the current regulations of Turkish Ministry of Health. As
the key factor of being a distributor requires taking precautions
against loosing the know-how, it is clearly foreseen for Turkish
distributors to review their contracts together with their
forecasts for near future.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Inquests are something which affect a vast range of NHS and private organisations, as well as individual clinicians, and so we provide a brief overview of recent developments as well as a couple of key potential changes to come.
Changes have been made to Turkey's cosmetics regulations. In particular, the amendments ban use of benzylidene camphor, as well as change requirements for non-oxidant hair dyes and the relationship between local and European Union legislation with regard to vivisection.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).